Pucotenlimab for children with LECC cancer
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug, pucotenlimab, for children and teens with a rare cancer called lymphoepithelioma-like carcinoma (LECC). The goal is to see if the drug is safe and helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The patient must be between 1 and 18 years old.
- They must have a rare cancer called lymphoepithelioma-like carcinoma (LECC) that has spread locally or to other parts of the body.
- They must be in good physical condition (ECOG score 0-1) and expected to live at least 6 months.
- They must have a tumor that can be measured on scans (like CT or MRI).
- They cannot have had prior immunotherapy with anti-PD-1 or anti-PD-L1 drugs (like Keytruda or Opdivo).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the immunotherapy drug Pucotenlimab to standard chemotherapy is safe and effective for children and teens with a type of muscle cancer (rhabdomyosarcoma) that is hard to treat. It may offer a new option for patients whose tumors are difficult to remove with surgery alone.
This trial tests two drugs given before surgery for penile cancer that has spread locally. The goal is to shrink the tumor and improve the chance of successful surgery.
This trial tests a combination of low-dose radiation, an immunotherapy drug called pucotenlimab, and chemotherapy for locally advanced rectal cancer that has not spread. The goal is to see if adding radiation helps shrink the tumor more effectively before surgery.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
This trial tests a combination of an immunotherapy (pucotenlimab), a targeted therapy (lenvatinib), and chemotherapy for children with advanced or relapsed hepatoblastoma that hasn't responded to prior treatment. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a new immunotherapy drug (pucotenlimab) combined with chemotherapy before surgery for head and neck cancer. The goal is to see if this combination shrinks the tumor and improves outcomes for patients with locally advanced disease.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.